Bing

Investors in Questcor Pharmaceuticals Inc (NASD: QCOR) saw new options begin trading today, for the November 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the QCOR options chain for the new November 1st …
Forbes · 10/3/2013
Monday sure didn’t do anything to disappoint those expectations for pharmaceuticals, adding upwards of $10 billion to the sector’s M&A tally. Roche contributed by far the least to total deal value, while anyone holding QCOR stock should be smiling.
Investor Place · ByDan Burrows · 4/7/2014
Questcor Pharmaceuticals, Inc. ( QCOR) was a big mover last session, as the company saw its shares shoot up nearly 19% on the day. This surge can be attributable to solid volume with far more shares changing hands than in a normal session. This …
NASDAQ · 4/8/2014
More from Bing News
The struggle between bulls and bears for directional control of Questcor (QCOR) stock is getting more complicated by the day. To get a specific recap on what happened since the Aetna (NYSE:AET) policy update in September, you can read my last article …
Seeking Alpha · 10/6/2012
Upcoming Aetna Policy Update has little downside, but lots of potential upside. Getting long QCOR now appears to make sense as the next major catalyst is Aetna's anticipated Policy Update on October 13th, which everyone expects will remain negative …
Reuters · 10/2/2012
ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial. Highlights from the ratings report include: QCOR's very impressive revenue growth greatly …
The Street · 10/19/2012
Questcor Pharmaceuticals, Inc. (QCOR) was a big mover last session, as the company saw its shares shoot up nearly 19% on the day. This surge can be attributable to solid volume with far more shares changing hands than in a normal session. This broke …
Yahoo Finance · 4/8/2014
Questcor Pharmaceuticals, Inc. (QCOR) is going all crazy'n stuff today following kick-butt quarter. Robust sales for Acthar put to rest worries that reimbursement issues for newer uses of the drug might restrict sales, and the stock is up more than 30% as ...
istock Analyst · 7/31/2013
Questcor Pharmaceuticals Inc (NASDAQ:QCOR) has faced the affects of bad press more than once in the past. The stock lost more than half of its value last year, after reports about its questionable marketing practices spurred a federal investigation.
INSIDER MONKEY · 5/8/2013
announces that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of purchasers of Questcor Pharmaceuticals, Inc. (“Questcor”) (Nasdaq: QCOR ) common stock during the period ...
The Motley Fool · 9/29/2012